Pricing & Access· June 24, 2026 · 25 min read
Amgen Portfolio Dossier: Purple Book Biologics and Biosimilars
By Ran Chen#Purple Book#Biosimilars#Drug Pricing
Topic
Purple Book
Biological product listings, biosimilar/interchangeable status, reference products, and exclusivity clues.
Biosimilars· June 24, 2026 · 17 min read
Darzalex Biosimilar Tracker: SC vs IV Formulations and the 2029 Market Entry Window
By Ran Chen#Biosimilars#Purple Book#Oncology
Pricing & Access· June 24, 2026 · 25 min read
Eli Lilly Portfolio Dossier: Diabetes, Obesity, and Insulin Pricing
Pricing & Access· June 24, 2026 · 26 min read
J&J Janssen Portfolio Dossier: Stelara Biosimilars and Oncology Assets
By Ran Chen#Purple Book#Orange Book#Biosimilars
Pricing & Access· June 24, 2026 · 25 min read
Novartis Portfolio Dossier: Spinoff Splits and Patent Cliffs
By Ran Chen#Orange Book#Purple Book#Generics
Pricing & Access· June 24, 2026 · 26 min read
Pfizer Portfolio Dossier: Patent Cliffs, Shortages, and Recalls
By Ran Chen#Orange Book#Purple Book#FDA Approval
Pricing & Access· June 24, 2026 · 26 min read
Roche Genentech Portfolio Dossier: Subcutaneous Biologic Transitions
By Ran Chen#Purple Book#Biosimilars#J-Code
Biosimilars· June 23, 2026 · 18 min read
Keytruda Biosimilar Tracker: The 7-Developer Race to the 2028 Cliff
By Ran Chen#Biosimilars#Oncology#FDA Approval
Biosimilars· June 16, 2026 · 11 min read
Interchangeable biosimilars in the Purple Book: 46 products, 12 reference biologics
By Ran Chen#Biosimilars#Interchangeability#Purple Book
Biosimilars· June 10, 2026 · 8 min read
Biosimilar competition decoded: 229 products across 20 reference drugs, one concentration
By Ran Chen#Biosimilars#Purple Book#Formulary Strategy